[Click eStock] "STCube, Successful Global Phase 1 Clinical Trial... Rising Expectations for Innovative New Drug"

[Asia Economy Reporter Jang Hyowon] KB Securities analyzed on the 9th that expectations are growing for STCube to be designated as a global innovative drug for immune checkpoint inhibitors following the successful results of its global Phase 1 clinical trial.

Researcher Im Sang-guk of KB Securities stated in a report on the same day, “The global Phase 1 clinical trial of the immune checkpoint inhibitor ‘Nelmastobat (hSTC810)’ confirmed safety at all doses, successfully meeting the primary endpoint of safety in Phase 1,” adding, “The DCR (Disease Control Rate) is maintained at approximately 43%, which is estimated to be similar to that of existing blockbuster immune checkpoint inhibitors on the market (such as Keytruda and Opdivo).”

The global Phase 1 clinical trial of Nelmastobat was designed to confirm additional safety and efficacy and determine the optimal dose through a backfill cohort. Encouraging results were observed, including new efficacy in patients with refractory solid tumors who relapsed after standard treatment and had limited treatment options, among those administered intermediate and high doses.

Researcher Im said, “Existing standard treatments for small cell lung cancer (SCLC) and ovarian cancer show a PFS (Progression-Free Survival) of about 2.1 to 4.1 months,” and added, “In the case of patients in this trial (monotherapy), the duration has reached and is well maintained beyond the existing PFS.”

He further stated, “If efficacy beyond the existing PFS is confirmed through these indications during Phase 2 clinical trials, accelerated approval may also be possible,” and predicted, “Thus, the global Phase 1 clinical trial of Nelmastobat is judged to be a successful Phase 1 result as an immune checkpoint inhibitor, confirming safety at all planned doses and maintaining efficacy in patients who already showed effectiveness. This will likely increase the possibility of commercialization plans and technology export with global big pharma companies in the future.”